<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Early detection of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is currently based on fecal occult blood testing (FOBT) and colonoscopy, both which can significantly reduce <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>-related mortality </plain></SENT>
<SENT sid="1" pm="."><plain>However, FOBT has low-sensitivity and specificity, whereas colonoscopy is labor- and cost-intensive </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, the discovery of novel biomarkers that can be used for improved <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> screening, diagnosis, staging and as targets for novel therapies is of utmost importance </plain></SENT>
<SENT sid="3" pm="."><plain>To identify novel <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> biomarkers we utilized representational difference analysis (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RDA</z:e>) and characterized a <z:hpo ids='HP_0003003'>colon cancer</z:hpo> associated transcript (CCAT1), demonstrating consistently strong expression in <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> of the colon, while being largely undetectable in <z:mpath ids='MPATH_458'>normal</z:mpath> human tissues (p &lt; 000.1) </plain></SENT>
<SENT sid="4" pm="."><plain>CCAT1 levels in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> are on average 235-fold higher than those found in <z:mpath ids='MPATH_458'>normal</z:mpath> mucosa </plain></SENT>
<SENT sid="5" pm="."><plain>Importantly, CCAT1 is strongly expressed in tissues representing the early phase of <z:mp ids='MP_0002006'>tumorigenesis</z:mp>: in <z:mpath ids='MPATH_490'>adenomatous polyps</z:mpath> and in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-proximal colonic epithelium, as well as in later stages of the disease (<z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e>, for example) </plain></SENT>
<SENT sid="6" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>-associated lymph nodes, CCAT1 overexpression is detectable in <z:hpo ids='HP_0000001'>all</z:hpo> H&amp;E positive, and 40.0% of H&amp;E and immunohistochemistry negative lymph nodes, suggesting very high sensitivity </plain></SENT>
<SENT sid="7" pm="."><plain>CCAT1 is also overexpressed in 40.0% of peripheral blood samples of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> but not in healthy controls </plain></SENT>
<SENT sid="8" pm="."><plain>CCAT1 is therefore a highly specific and readily detectable marker for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-associated tissues </plain></SENT>
</text></document>